Regulus Therapeutics

Company profile

About

Regulus Therapeutics (NASDAQ:RGLS) is a biopharmaceutical company focused on developing innovative treatments for chronic diseases. With a deep commitment to scientific exploration and patient care, Regulus aims to unlock new pathways in disease management through its RNA-targeted therapeutics platform. The company’s projects primarily address conditions with significant unmet medical needs, including kidney diseases, hepatitis C, and cancer. Through rigorous research and clinical trials, Regulus strives to bring forth novel drugs that improve patients’ lives. Among its objectives, the company places a strong emphasis on achieving clinical advancement for its leading drug candidates, ensuring regulatory success, and forging strategic partnerships to enhance drug development and commercialization efforts.

Snapshot

2007Year founded

30Employees

Carlsbad, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

Carlsbad, US

Products and/or services of Regulus Therapeutics

Development of RG-012 for the treatment of Alport syndrome, targeting microRNAs involved in the disease's progression.
Advancing RGLS4326 for the treatment of Autosomal Dominant Polycystic Kidney Disease, focusing on microRNA-17.
Collaboration on microRNA-targeted therapies for Hepatitis C, leveraging the antiviral potential of microRNA manipulation.
Research into microRNA therapeutics for cardiovascular diseases, exploring the regulation of genes involved in heart function.
Investigation into treatments for Metabolic Disorders, aiming to correct metabolic imbalances through microRNA pathways.
Preclinical development of cancer therapeutics, focusing on microRNA strategies to suppress tumor growth and progression.